<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hu J</submitter><funding>American Cancer Society (American Cancer Society, Inc.)</funding><pagination>2892-2904</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10516751</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(39)</volume><pubmed_abstract>Hepatic cholesterol accumulation and hypercholesterolemia are implicated in hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol-lowering drugs on HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated. A positive feedback between cholesterol synthesis and the pentose phosphate pathway (PPP) rather than glycolysis was formed in tumors of c-Myc mice. Blocking the PPP prevented cholesterol synthesis and thereby HCC in c-Myc mice, while ablating glycolysis did not affect cholesterol synthesis and failed to prevent c-Myc-induced HCC. Unexpectedly, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) and G6PD (glucose-6-phosphate dehydrogenase), the rate-limiting enzymes of cholesterol synthesis and the PPP, were identified as direct targets of microRNA-206. By targeting Hmgcr and G6pd, microRNA-206 disrupted the positive feedback and fully prevented HCC in c-Myc mice, while 100% of control mice died of HCC. Disrupting the interaction of microRNA-206 with Hmgcr and G6pd restored cholesterol synthesis, the PPP and HCC growth that was inhibited by miR-206. This study identified a previously undescribed positive feedback loop between cholesterol synthesis and the PPP, which drives HCC, while microRNA-206 prevents HCC by disrupting this loop. Cholesterol synthesis as a process rather than cholesterol itself is the major contributor of HCC.</pubmed_abstract><journal>Oncogene</journal><pubmed_title>A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma.</pubmed_title><pmcid>PMC10516751</pmcid><funding_grant_id>IS-16-210-01-RMC</funding_grant_id><pubmed_authors>Hu J</pubmed_authors><pubmed_authors>Liu N</pubmed_authors><pubmed_authors>Steer CJ</pubmed_authors><pubmed_authors>Song D</pubmed_authors><pubmed_authors>Zheng G</pubmed_authors><pubmed_authors>Song G</pubmed_authors></additional><is_claimable>false</is_claimable><name>A positive feedback between cholesterol synthesis and the pentose phosphate pathway rather than glycolysis promotes hepatocellular carcinoma.</name><description>Hepatic cholesterol accumulation and hypercholesterolemia are implicated in hepatocellular carcinoma (HCC). However, the therapeutic effects of cholesterol-lowering drugs on HCC are controversial, indicating that the relationship between cholesterol metabolism and HCC is more complex than anticipated. A positive feedback between cholesterol synthesis and the pentose phosphate pathway (PPP) rather than glycolysis was formed in tumors of c-Myc mice. Blocking the PPP prevented cholesterol synthesis and thereby HCC in c-Myc mice, while ablating glycolysis did not affect cholesterol synthesis and failed to prevent c-Myc-induced HCC. Unexpectedly, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) and G6PD (glucose-6-phosphate dehydrogenase), the rate-limiting enzymes of cholesterol synthesis and the PPP, were identified as direct targets of microRNA-206. By targeting Hmgcr and G6pd, microRNA-206 disrupted the positive feedback and fully prevented HCC in c-Myc mice, while 100% of control mice died of HCC. Disrupting the interaction of microRNA-206 with Hmgcr and G6pd restored cholesterol synthesis, the PPP and HCC growth that was inhibited by miR-206. This study identified a previously undescribed positive feedback loop between cholesterol synthesis and the PPP, which drives HCC, while microRNA-206 prevents HCC by disrupting this loop. Cholesterol synthesis as a process rather than cholesterol itself is the major contributor of HCC.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2024-11-21T05:29:26.022Z</modification><creation>2024-11-21T05:29:26.022Z</creation></dates><accession>S-EPMC10516751</accession><cross_references><pubmed>37596320</pubmed><doi>10.1038/s41388-023-02757-9</doi></cross_references></HashMap>